Conor wins favourable UK ruling in Angiotech paclitaxel dispute
This article was originally published in Clinica
Executive Summary
Conor Medsystems saw its shares hitting an all-time high last week after a UK court verdict rendered a paclitaxel patent held by the firm's legal adversary Angiotech Pharmaceuticals invalid. The ruling, handed down on February 24, comes just a week after Conor CE-marked its cobalt chromium, paclitaxel-eluting CoStar stent (see Clinica No 1195, p 3).
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.